Peter Collum
Director of Finance/CFO at REDX PHARMA PLC
Net worth: 29 040 $ as of 2024-04-29
Peter Collum active positions
| Companies | Position | Start | End |
|---|---|---|---|
| REDX PHARMA PLC | Director of Finance/CFO | 2021-05-04 | - |
Career history of Peter Collum
Former positions of Peter Collum
| Companies | Position | Start | End |
|---|---|---|---|
| PHARNEXT SCA | Director of Finance/CFO | 2019-06-25 | 2021-03-31 |
MTS Health Partners LP
 MTS Health Partners LP Investment Banks/BrokersFinance MTS Health Partners LP provides strategic and financial advisory services to healthcare companies from global corporations to venture backed businesses. Its strategic advisory alternatives include mergers, acquisitions, company sales, divestitures, recapitalizations, restructurings, general strategic advisory, financing oversight and oversight opinions. The firms financing solutions include traditional private convertible preferred issuances, cross-over focused convertible transactions, common stock and structured/convertible PIPEs, registered direct and acquisition financings, secondary sales, special situations, structured debt financings and royalty monetization. The company was founded by Curtis Scott Lane in 2000 and is headquartered in New York, NY. | Corporate Officer/Principal | 2009-05-31 | 2019-05-31 |
| MERRILL LYNCH PREFERRED CAPITAL TRUST I | Corporate Officer/Principal | 2008-12-31 | 2008-12-31 |
Hoffmann-La Roche, Inc.
 Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Corporate Officer/Principal | 1999-12-31 | 1999-12-31 |
Training of Peter Collum
| Rutgers State University of New Jersey | Undergraduate Degree |
| The University of Chicago Booth School of Business | Masters Business Admin |
Statistics
International
| United States | 5 |
| France | 3 |
| United Kingdom | 2 |
Operational
| Corporate Officer/Principal | 3 |
| Director of Finance/CFO | 2 |
| Undergraduate Degree | 1 |
Sectoral
| Health Technology | 4 |
| Finance | 3 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 3 |
|---|---|
| MERRILL LYNCH PREFERRED CAPITAL TRUST I | Finance |
| PHARNEXT SCA | Health Technology |
| REDX PHARMA PLC | Health Technology |
| Private companies | 2 |
|---|---|
MTS Health Partners LP
MTS Health Partners LP Investment Banks/BrokersFinance MTS Health Partners LP provides strategic and financial advisory services to healthcare companies from global corporations to venture backed businesses. Its strategic advisory alternatives include mergers, acquisitions, company sales, divestitures, recapitalizations, restructurings, general strategic advisory, financing oversight and oversight opinions. The firms financing solutions include traditional private convertible preferred issuances, cross-over focused convertible transactions, common stock and structured/convertible PIPEs, registered direct and acquisition financings, secondary sales, special situations, structured debt financings and royalty monetization. The company was founded by Curtis Scott Lane in 2000 and is headquartered in New York, NY. | Finance |
Hoffmann-La Roche, Inc.
Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Health Technology |
- Stock Market
- Insiders
- Peter Collum
- Experience
